paroxetine has been researched along with Benign Neoplasms in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 6 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Boldt, G; Bruera, E; Chiu, L; Chow, R; Lock, M; Prsic, E; Sanatani, M | 1 |
| Doss C, GP; Kumar S, U; Tayubi, IA | 1 |
| Crandall, CJ; Manson, JE; Mehta, JM | 1 |
| Alexander, M; Fullerton, S; Simadri, K; Thakerar, A | 2 |
| Hong, J; Hui, L; Wong, AB | 1 |
| Alfano, CM; Heckler, C; Kleckner, AS; Kleckner, IR; Leach, CR; Miller, SM; Mohr, D; Mustian, KM; Palesh, OG; Peppone, LJ; Piper, BF; Scarpato, J; Smith, T; Sprod, LK | 1 |
| Hotopf, M; Minton, O; Richardson, A; Sharpe, M; Stone, P | 1 |
| Palshof, T; Pedersen, L | 1 |
| Amodeo, L; Biancofiore, A; Castelli, L; Cipriani, D; Leombruni, P; Torta, R | 1 |
| Dasgupta, K; Labos, C; Nedjar, H; Rahme, E; Turecki, G | 1 |
| Fiscella, K; Heckler, C; Innominato, PF; Janelsins, M; Kesler, S; Manber, R; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Roth, T; Sprod, LK | 1 |
| Berard, RM | 1 |
| Costantini, M; Krajnik, M; Sorge, AA; Zylicz, Z | 1 |
| Andrews, PL; Banerjee, TK; Flynn, PJ; Hickok, JT; Hynes, HE; King, DK; Kirshner, JJ; Morrow, GR; Raubertas, RF; Roscoe, JA | 1 |
| Hariharan, B; Rajagopal, MR | 1 |
| Conti, M; Frasnelli, M; Rosetti, M; Tesei, A; Zoli, W | 1 |
| Krajnik, M; Smits, C; Zylicz, Z | 1 |
| McNeil, C | 1 |
| Capuron, L; Gumnick, JF; Lawson, DH; Miller, AH; Musselman, DL; Nemeroff, CB; Reemsnyder, A | 1 |
7 review(s) available for paroxetine and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Network Meta-Analysis; Paroxetine | 2023 |
Management of Menopausal Symptoms: A Review.
Topics: Autonomic Nervous System Diseases; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Female Urogenital Diseases; Hot Flashes; Humans; Medroxyprogesterone Acetate; Menopause; Neoplasms; Paroxetine; Sweating; Venlafaxine Hydrochloride; Venous Thromboembolism | 2023 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphenidate Hydrochloride; Dextroamphetamine; Exercise Therapy; Fatigue; Glucocorticoids; Humans; Methylphenidate; Methylprednisolone; Modafinil; Neoplasms; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Wakefulness-Promoting Agents | 2017 |
A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue.
Topics: Anemia; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Central Nervous System Stimulants; Darbepoetin alfa; Dopamine Uptake Inhibitors; Erythropoietin; Fatigue; Hematinics; Humans; Methylphenidate; Neoplasms; Odds Ratio; Paroxetine; Progestins; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
[Pharmaceutical treatment of cancer-associated fatigue--a survey of a Cochrane review].
Topics: Antidepressive Agents, Second-Generation; Central Nervous System Stimulants; Erythropoietin; Evidence-Based Medicine; Fatigue; Hematinics; Humans; Methylphenidate; Neoplasms; Paroxetine; Progestins; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2009 |
Depression and anxiety in oncology: the psychiatrist's perspective.
Topics: Adolescent; Adult; Antidepressive Agents; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder; Humans; Medical Oncology; Neoplasms; Paroxetine; Personality Inventory; Prevalence; Psychiatric Status Rating Scales; Psychiatry; Risk Factors; Selective Serotonin Reuptake Inhibitors | 2001 |
5 trial(s) available for paroxetine and Benign Neoplasms
| Article | Year |
|---|---|
Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study.
Topics: Adjustment Disorders; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Schedule; Dysthymic Disorder; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Time Factors | 2012 |
Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Depression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasms; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders; Treatment Outcome; Young Adult | 2012 |
Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cross-Over Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paroxetine; Pruritus; Treatment Outcome | 2003 |
Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Depression; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Neoplasms; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2003 |
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Chi-Square Distribution; Double-Blind Method; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Mood Disorders; Neoplasms; Paroxetine; Patients; Statistics, Nonparametric | 2002 |
9 other study(ies) available for paroxetine and Benign Neoplasms
| Article | Year |
|---|---|
Identification of potential inhibitors, conformational dynamics, and mechanistic insights into mutant Kirsten rat sarcoma virus (G13D) driven cancers.
Topics: Humans; Kirsten murine sarcoma virus; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms; Paroxetine; Prospective Studies; Proto-Oncogene Proteins p21(ras); Tramadol | 2022 |
Paroxetine for the treatment of intractable and persistent cough in patients diagnosed with cancer.
Topics: Adult; Aged; Aged, 80 and over; Australia; Cough; Female; Humans; Male; Middle Aged; Neoplasms; Paroxetine; Quality of Life; Retrospective Studies | 2020 |
Potential medication interactions with paroxetine use for cough in cancer patients.
Topics: Cough; Drug Interactions; Humans; Neoplasms; Paroxetine | 2020 |
Author's response to letter: Paroxetine for the treatment of intractable and persistent cough in patients diagnosed with cancer.
Topics: Cough; Humans; Neoplasms; Paroxetine | 2020 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Canada; Citalopram; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Heart Failure; Hemorrhage; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Neoplasms; Paroxetine; Peptic Ulcer; Platelet Aggregation Inhibitors; Renal Insufficiency; Retrospective Studies; Risk; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Ticlopidine | 2011 |
Re: Paroxetine in the treatment of severe non-dermatological pruritus.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cross-Over Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paroxetine; Pruritus; Severity of Illness Index; Treatment Outcome | 2005 |
Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells.
Topics: Animals; Antidepressive Agents; Benzimidazoles; Biological Transport; Cell Line, Tumor; Cyclohexanols; Fibroblasts; Humans; Ions; Mice; Necrosis; Neoplasms; Paroxetine; Propidium; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2006 |
Paroxetine for pruritus in advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Child, Preschool; Humans; Male; Middle Aged; Neoplasms; Paroxetine; Pruritus; Selective Serotonin Reuptake Inhibitors | 1998 |
Cancer fatigue: one drug fails but more are in the pipeline.
Topics: Clinical Trials as Topic; Depression; Dexamethasone; Fatigue; Humans; Neoplasms; Paroxetine; Prednisolone; Selective Serotonin Reuptake Inhibitors; Treatment Failure | 2001 |